Research Use Only Peptides: What FDA Says the Label Means

On this page

A “research use only” label can look like a legal category. In FDA’s 2026 warning letters to peptide sellers, FDA said the label did not change its conclusion. This guide explains what FDA wrote, what it treated as evidence, and what the letters do not prove.

The short answer

“Research use only” is a phrase on a label, not a status FDA recognizes as protecting a product. In letters dated March 31 and Aug. 24, 2026, FDA told sellers of “research” peptides that, despite such labels, evidence on their own websites established that the products were intended for human use. FDA called the products unapproved new drugs.

What that does and does not mean. These are FDA’s positions in warning letters, as of their dates. They are not court rulings, and they concern sellers, not buyers. We found no FDA statement that a “research use only” product is safe, tested or approved.

How this guide is built

This is an explainer, not a ranking. It reports what FDA said in letters we read at fda.gov, and it attributes each statement to FDA. It does not name sellers and does not link to them. It gives no doses, preparation steps or buying guidance. For the broader picture of approved, compounded and “research” products, see are peptides legal in the US. For every letter we found, see the FDA warning letters tracker on our sister site, Best Peptides Today.

What does “research use only” mean on a label?

On a product page it is a seller’s statement about how the product may be used. It is not an FDA classification, and FDA did not treat it as decisive. The phrases FDA quoted from sellers’ labels in the letters we read include:

What did FDA say about the label?

In the March 31 letters, FDA wrote that “despite statements on your product labeling marketing your products for” research purposes, “evidence obtained from your website establishes that your products are intended to be drugs for human use” (example). The August letters make the same point with the labels shown above.

Two patterns stand out:

• The same argument appears in two batches. FDA sent five letters of this kind on March 31, 2026 and five on Aug. 24, 2026. In the letters quoted here, the label did not change FDA’s conclusion.
• The legal hook is “intended use.” The letters say a product is a drug if it is intended to diagnose, cure, treat or prevent disease, or to affect the structure or function of the body, and they cite a company’s own web pages as evidence of intent (example).

We count at least 12 letters since January 2025 that went to sellers of “research” peptides, out of 149 letters naming peptide drugs. Our search of FDA’s site may not have caught every letter, so treat these as minimums (tracker).

What did FDA treat as evidence of human use?

In the three August letters we studied in detail, FDA reviewed the companies’ websites in July 2026. According to the letters (one, two, three), the evidence included:

• Descriptions of effects on the sites, such as weight loss, blood sugar control, appetite and libido.
• Comparisons of products by clinical weight-loss results, in one letter.
• Bacteriostatic water sold alongside the peptides. In two letters, FDA said selling water to reconstitute injectable peptides together with the peptides shows intent that the water be used for injection, so it treated the water as a drug too.
• Calculators and guides. In two letters, FDA described a “peptide calculator” (and, in one, a “peptide guide”) as resources that provide “the means to prepare an injectable drug for human administration.” We do not describe how such preparation works.

Which products did FDA name, and are they approved?

FDA’s conclusion in each letter is about that company’s product, which it says has no approved application. It is not a statement about the molecule. Among the molecules named in the letters cited here:

So FDA is not saying that semaglutide or tirzepatide as medicines are unapproved. It is saying that a “research” product sold by a company without an application is an unapproved drug. We did not review the quality of any seller’s product.

How is this different from compounding?

They are different channels:

• Compounded drugs are made by a licensed pharmacist or physician for an individual patient under a prescription. They are not FDA-approved, and FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. For GLP-1 drugs, see what FDA says about compounded GLP-1 drugs, including FDA’s statement on “research” versions.
• “Research use only” products are sold by companies, with the label as the only claim about purpose, and the letters say FDA does not accept that label as decisive.
• HHS’s Oct. 30, 2026 interim policy concerns compounding under section 503A for six peptides. HHS says the policy “will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients” (HHS policy). It names state-licensed pharmacies, federal facilities and licensed physicians. As we read it, it does not extend to web sellers, and none of the products named in the letters we cite is on its Appendix A. It is enforcement discretion, not FDA approval. See the Federal Register notice.

What risks does FDA describe?

• Unknown quality. FDA’s page on unapproved GLP-1 drugs says products of this kind are “of unknown quality and may be harmful”, and that FDA has warned companies selling unapproved drugs falsely labeled “for research purposes” or “not for human consumption.”
• Injectables raise the stakes. The letters say injectable drugs can pose risks of serious harm to users because they bypass some of the body’s defenses against toxins and microorganisms.
• No approved application. FDA said in the letters that no approved application is in effect for the products.

We did not test any product, and the letters concern website claims and marketing, not lab results.

What does a warning letter not prove?

• It is not a ruling. A warning letter states FDA’s findings and position on the facts it reviewed. Each of the August letters gave the company 15 business days to respond. We have not checked any response or later action.
• It is not a finding about product quality. The letters concern website claims and marketing.
• It is not a full list of violations or of sellers. The letters say they are “not intended to be an all-inclusive list of the violations.”
• It does not say what any buyer did. The letters concern sellers.
• A warning about seizure is not a seizure. The letters warn that failure to address violations “may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.” That is a warning, not an action taken.

What signs did FDA cite that a “research” product is meant for people?

Based on the letters, these are the kinds of evidence FDA relied on. A label alone was not enough for FDA to reach a different conclusion:

• A site describes the product’s effects on the body, or compares products by clinical results.
• Bacteriostatic water is sold alongside the product.
• A “peptide calculator” or “peptide guide” is offered on the site.

Finding one of these does not tell you whether a product is safe or legal to use. It tells you what FDA has pointed to in its own letters.

What should you ask your doctor or pharmacist?

• If I am interested in a peptide, is there an FDA-approved option for my goal?
• If a product is offered to me, is it FDA-approved, compounded for me by a licensed pharmacy, or sold as “research”? Who made it?
• What is known about its safety in people?
• Whom do I report a bad reaction to? (FDA runs MedWatch.)

We do not give doses, preparation steps or buying guidance, and we do not recommend or link to sellers.

Frequently asked questions

Is “research use only” a legal category?

FDA does not treat the label as protecting a product. In its March 31 and Aug. 24, 2026 letters, FDA said that despite such labels, evidence on the sellers’ websites established that the products were intended for human use.

Are research peptides legal to buy?

We do not give a yes or no. The letters concern sellers and say nothing about what a buyer did. FDA called the sellers’ products unapproved new drugs.

Does “not for human consumption” make a product safe or lawful?

In the letters we read, FDA said such wording did not change its conclusion. FDA’s page says products of this kind are “of unknown quality and may be harmful.”

Is a research peptide the same as a compounded one?

No. A compounded drug is prepared by a licensed pharmacy or physician for a patient under a prescription, and it is not FDA-approved. A “research” product is sold by a company under a research label.

Does HHS’s new peptide policy cover research peptides?

No. As we read it, the Oct. 30, 2026 interim policy covers compounding under section 503A for six peptides and HHS says it “will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers.” It is not an approval.

From Best Peptides Today

1. What FDA's Warning Letters Say About 'Research Use Only' PeptidesOct. 31, 2026
2. FDA Warning Letters on Peptides: A Running TrackerNov. 3, 2026
3. Peptide Regulatory Changelog Since January 2025Nov. 3, 2026

Sources we checked

1. FDA Warning Letter 733652 (Aug. 24, 2026)FDA. Accessed November 3, 2026.
2. FDA Warning Letter 735067 (Aug. 24, 2026)FDA. Accessed November 3, 2026.
3. FDA Warning Letter 734884 (Aug. 24, 2026)FDA. Accessed November 3, 2026.
4. FDA Warning Letter 735063 (Aug. 24, 2026)FDA. Accessed November 3, 2026.
5. FDA Warning Letter 735127 (Aug. 24, 2026)FDA. Accessed November 3, 2026.
6. FDA Warning Letter 721600 (Mar. 31, 2026)FDA. Accessed November 3, 2026.
7. FDA Warning Letter 721088 (Mar. 31, 2026)FDA. Accessed November 3, 2026.
8. FDA Warning Letter 721806 (Mar. 31, 2026)FDA. Accessed November 3, 2026.
9. FDA warning letters pageFDA. Accessed November 3, 2026.
10. Best Peptides Today: FDA warning letters that name peptide drugs (tracker)Other. Accessed November 3, 2026.
11. FDA: FDA's concerns with unapproved GLP-1 drugs used for weight lossFDA. Accessed November 3, 2026.
12. Federal Register: HHS enforcement discretion policy on 503A peptide compounding (Oct. 30, 2026)Other. Accessed November 3, 2026.
13. HHS: Enforcement Discretion Policy, with Appendices A and BOther. Accessed November 3, 2026.
14. Drugs@FDA (searched Nov. 4, 2026; no product listed as retatrutide, survodutide, mazdutide or ipamorelin)FDA. Accessed November 4, 2026.
15. FDA MedWatch: Safety information and adverse event reporting programFDA. Accessed November 3, 2026.

Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.